Rubicon Research Limited (“Rubicon” or the “Company”) today announced the acquisition of an 85% equity ownership in Arinna Lifesciences Limited (“Arinna”) from its current shareholders.    With a portfolio of over 60 brands in chronic therapies, Arinna is one of the few domestic formulations companies principally focused